Drugs / HH-009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07547553 | May 2026 → Oct 2028 expected | hepatocellular carcinoma | Huahui Health | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-08-19 | Huahui Health | Huahui's "First-in-Class"Anti-Tumor Drug Candidate HH-009 Completed Its First-Dose-in-Human huahuihealth.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HH-009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07547553 ↗ |